APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pulmonary Hypertension Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Pulmonary Hypertension Drug Industry Growth and Trends Forecast to 2032

26 December 202592 pages

Choose your research edition.

Industry ResearchPulmonary Hypertension Drug Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Pulmonary Hypertension Drug Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Pulmonary Hypertension Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pulmonary Hypertension Drug Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Pulmonary Hypertension Drug Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Pulmonary Hypertension Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Pulmonary Hypertension Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Pulmonary Hypertension Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pulmonary Hypertension Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Pulmonary Hypertension Drug include Biolab Sanus Farmaceutica Ltda., Hanmi Pharmaceuticals, Co. Ltd., Ikaria Inc., Proreo Pharma AG, Vectura Group plc, Vicore Pharma AB, Bayer AG and Sanofi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Pulmonary Hypertension Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Pulmonary Hypertension Drug market size, estimates, and forecasts are presented in terms of sales volume (W Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Pulmonary Hypertension Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Pulmonary Hypertension Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Pulmonary Hypertension Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Pulmonary Hypertension Drug Market by Company

Biolab Sanus Farmaceutica Ltda.

Hanmi Pharmaceuticals, Co. Ltd.

Ikaria Inc.

Proreo Pharma AG

Vectura Group plc

Vicore Pharma AB

Bayer AG

Sanofi

Pulmonary Hypertension Drug Segment by Type

IK-3001

Riociguat

Sildenafil Citrate IMD

SAR-407899

IK-7002

Others

Pulmonary Hypertension Drug Segment by Application

Clinic

Hospital

Others

Pulmonary Hypertension Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pulmonary Hypertension Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pulmonary Hypertension Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pulmonary Hypertension Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Pulmonary Hypertension Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Pulmonary Hypertension Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of IK-3001 Table 2. Major Company of Riociguat Table 3. Major Company of Sildenafil Citrate IMD Table 4. Major Company of SAR-407899 Table 5. Major Company of IK-7002 Table 6. Major Company of Others Table 7. Global Pulmonary Hypertension Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 8. Global Pulmonary Hypertension Drug Sales by Type (2021-2026) & (W Units) Table 9. Global Pulmonary Hypertension Drug Sales Market Share in Volume by Type (2021-2026) Table 10. Global Pulmonary Hypertension Drug Sales by Type (2021-2026) & (US$ Million) Table 11. Global Pulmonary Hypertension Drug Sales Market Share in Value by Type (2021-2026) Table 12. Global Pulmonary Hypertension Drug Price by Type (2021-2026) & (US$/Unit) Table 13. Global Pulmonary Hypertension Drug Sales by Type (2027-2032) & (W Units) Table 14. Global Pulmonary Hypertension Drug Sales Market Share in Volume by Type (2027-2032) Table 15. Global Pulmonary Hypertension Drug Sales by Type (2027-2032) & (US$ Million) Table 16. Global Pulmonary Hypertension Drug Sales Market Share in Value by Type (2027-2032) Table 17. Global Pulmonary Hypertension Drug Price by Type (2027-2032) & (US$/Unit) Table 18. North America Pulmonary Hypertension Drug Sales by Type (2021-2026) & (W Units) Table 19. North America Pulmonary Hypertension Drug Sales by Type (2021-2026) & (US$ Million) Table 20. Europe Pulmonary Hypertension Drug Sales by Type (2021-2026) & (W Units) Table 21. Europe Pulmonary Hypertension Drug Sales by Type (2021-2026) & (US$ Million) Table 22. Asia-Pacific Pulmonary Hypertension Drug Sales by Type (2021-2026) & (W Units) Table 23. Asia-Pacific Pulmonary Hypertension Drug Sales by Type (2021-2026) & (US$ Million) Table 24. Latin America Pulmonary Hypertension Drug Sales by Type (2021-2026) & (W Units) Table 25. Latin America Pulmonary Hypertension Drug Sales by Type (2021-2026) & (US$ Million) Table 26. Middle East and Africa Pulmonary Hypertension Drug Sales by Type (2021-2026) & (W Units) Table 27. Middle East and Africa Pulmonary Hypertension Drug Sales by Type (2021-2026) & (US$ Million) Table 28. Pulmonary Hypertension Drug Industry Trends Table 29. Pulmonary Hypertension Drug Industry Drivers Table 30. Pulmonary Hypertension Drug Industry Opportunities and Challenges Table 31. Pulmonary Hypertension Drug Industry Restraints Table 32. Global Pulmonary Hypertension Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 33. Global Pulmonary Hypertension Drug Revenue Market Share by Company (2021-2026) Table 34. Global Pulmonary Hypertension Drug Sales by Company (2021-2026) & (W Units) Table 35. Global Pulmonary Hypertension Drug Sales Share by Company (2021-2026) Table 36. Global Pulmonary Hypertension Drug Market Price by Company (2021-2026) & (US$/Unit) Table 37. Global Pulmonary Hypertension Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 38. Global Pulmonary Hypertension Drug Major Company Production Sites and Headquarters Table 39. Global Pulmonary Hypertension Drug Company, Product Type & Application Table 40. Global Pulmonary Hypertension Drug Company Establishment Date Table 41. Global Company Market Concentration Ratio (CR5 and HHI) Table 42. Global Pulmonary Hypertension Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 43. Global Pulmonary Hypertension Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 44. Global Pulmonary Hypertension Drug Sales by Region (2021-2026) & (W Units) Table 45. Global Pulmonary Hypertension Drug Sales Market Share in Volume by Region (2021-2026) Table 46. Global Pulmonary Hypertension Drug Sales by Region (2021-2026) & (US$ Million) Table 47. Global Pulmonary Hypertension Drug Sales Market Share in Value by Region (2021-2026) Table 48. Global Pulmonary Hypertension Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 49. Global Pulmonary Hypertension Drug Sales by Region (2027-2032) & (W Units) Table 50. Global Pulmonary Hypertension Drug Sales Market Share in Volume by Region (2027-2032) Table 51. Global Pulmonary Hypertension Drug Sales by Region (2027-2032) & (US$ Million) Table 52. Global Pulmonary Hypertension Drug Sales Market Share in Value by Region (2027-2032) Table 53. Global Pulmonary Hypertension Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 54. Global Pulmonary Hypertension Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 55. Global Pulmonary Hypertension Drug Sales by Application (2021-2026) & (W Units) Table 56. Global Pulmonary Hypertension Drug Sales Market Share in Volume by Application (2021-2026) Table 57. Global Pulmonary Hypertension Drug Sales by Application (2021-2026) & (US$ Million) Table 58. Global Pulmonary Hypertension Drug Sales Market Share in Value by Application (2021-2026) Table 59. Global Pulmonary Hypertension Drug Price by Application (2021-2026) & (US$/Unit) Table 60. Global Pulmonary Hypertension Drug Sales by Application (2027-2032) & (W Units) Table 61. Global Pulmonary Hypertension Drug Sales Market Share in Volume by Application (2027-2032) Table 62. Global Pulmonary Hypertension Drug Sales by Application (2027-2032) & (US$ Million) Table 63. Global Pulmonary Hypertension Drug Sales Market Share in Value by Application (2027-2032) Table 64. Global Pulmonary Hypertension Drug Price by Application (2027-2032) & (US$/Unit) Table 65. North America Pulmonary Hypertension Drug Sales by Application (2021-2026) & (W Units) Table 66. North America Pulmonary Hypertension Drug Sales by Application (2021-2026) & (US$ Million) Table 67. Europe Pulmonary Hypertension Drug Sales by Application (2021-2026) & (W Units) Table 68. Europe Pulmonary Hypertension Drug Sales by Application (2021-2026) & (US$ Million) Table 69. Asia-Pacific Pulmonary Hypertension Drug Sales by Application (2021-2026) & (W Units) Table 70. Asia-Pacific Pulmonary Hypertension Drug Sales by Application (2021-2026) & (US$ Million) Table 71. Latin America Pulmonary Hypertension Drug Sales by Application (2021-2026) & (W Units) Table 72. Latin America Pulmonary Hypertension Drug Sales by Application (2021-2026) & (US$ Million) Table 73. Middle East and Africa Pulmonary Hypertension Drug Sales by Application (2021-2026) & (W Units) Table 74. Middle East and Africa Pulmonary Hypertension Drug Sales by Application (2021-2026) & (US$ Million) Table 75. Biolab Sanus Farmaceutica Ltda. Company Information Table 76. Biolab Sanus Farmaceutica Ltda. Business Overview Table 77. Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Product Portfolio Table 79. Biolab Sanus Farmaceutica Ltda. Recent Development Table 80. Hanmi Pharmaceuticals, Co. Ltd. Company Information Table 81. Hanmi Pharmaceuticals, Co. Ltd. Business Overview Table 82. Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Product Portfolio Table 84. Hanmi Pharmaceuticals, Co. Ltd. Recent Development Table 85. Ikaria Inc. Company Information Table 86. Ikaria Inc. Business Overview Table 87. Ikaria Inc. Pulmonary Hypertension Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Ikaria Inc. Pulmonary Hypertension Drug Product Portfolio Table 89. Ikaria Inc. Recent Development Table 90. Proreo Pharma AG Company Information Table 91. Proreo Pharma AG Business Overview Table 92. Proreo Pharma AG Pulmonary Hypertension Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Proreo Pharma AG Pulmonary Hypertension Drug Product Portfolio Table 94. Proreo Pharma AG Recent Development Table 95. Vectura Group plc Company Information Table 96. Vectura Group plc Business Overview Table 97. Vectura Group plc Pulmonary Hypertension Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Vectura Group plc Pulmonary Hypertension Drug Product Portfolio Table 99. Vectura Group plc Recent Development Table 100. Vicore Pharma AB Company Information Table 101. Vicore Pharma AB Business Overview Table 102. Vicore Pharma AB Pulmonary Hypertension Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Vicore Pharma AB Pulmonary Hypertension Drug Product Portfolio Table 104. Vicore Pharma AB Recent Development Table 105. Bayer AG Company Information Table 106. Bayer AG Business Overview Table 107. Bayer AG Pulmonary Hypertension Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Bayer AG Pulmonary Hypertension Drug Product Portfolio Table 109. Bayer AG Recent Development Table 110. Sanofi Company Information Table 111. Sanofi Business Overview Table 112. Sanofi Pulmonary Hypertension Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Sanofi Pulmonary Hypertension Drug Product Portfolio Table 114. Sanofi Recent Development Table 115. North America Pulmonary Hypertension Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 116. North America Pulmonary Hypertension Drug Sales by Country (2021-2026) & (W Units) Table 117. North America Pulmonary Hypertension Drug Sales Market Share by Country (2021-2026) Table 118. North America Pulmonary Hypertension Drug Sales Forecast by Country (2027-2032) & (W Units) Table 119. North America Pulmonary Hypertension Drug Sales Market Share Forecast by Country (2027-2032) Table 120. North America Pulmonary Hypertension Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 121. North America Pulmonary Hypertension Drug Market Size by Country (2021-2026) & (US$ Million) Table 122. North America Pulmonary Hypertension Drug Market Share by Country (2021-2026) Table 123. North America Pulmonary Hypertension Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 124. North America Pulmonary Hypertension Drug Market Share Forecast by Country (2027-2032) Table 125. Europe Pulmonary Hypertension Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 126. Europe Pulmonary Hypertension Drug Sales by Country (2021-2026) & (W Units) Table 127. Europe Pulmonary Hypertension Drug Sales Market Share by Country (2021-2026) Table 128. Europe Pulmonary Hypertension Drug Sales Forecast by Country (2027-2032) & (W Units) Table 129. Europe Pulmonary Hypertension Drug Sales Market Share Forecast by Country (2027-2032) Table 130. Europe Pulmonary Hypertension Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 131. Europe Pulmonary Hypertension Drug Market Size by Country (2021-2026) & (US$ Million) Table 132. Europe Pulmonary Hypertension Drug Market Share by Country (2021-2026) Table 133. Europe Pulmonary Hypertension Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 134. Europe Pulmonary Hypertension Drug Market Share Forecast by Country (2027-2032) Table 135. Asia-Pacific Pulmonary Hypertension Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 136. Asia-Pacific Pulmonary Hypertension Drug Sales by Country (2021-2026) & (W Units) Table 137. Asia-Pacific Pulmonary Hypertension Drug Sales Market Share by Country (2021-2026) Table 138. Asia-Pacific Pulmonary Hypertension Drug Sales Forecast by Country (2027-2032) & (W Units) Table 139. Asia-Pacific Pulmonary Hypertension Drug Sales Market Share Forecast by Country (2027-2032) Table 140. Asia-Pacific Pulmonary Hypertension Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 141. Asia-Pacific Pulmonary Hypertension Drug Market Size by Country (2021-2026) & (US$ Million) Table 142. Asia-Pacific Pulmonary Hypertension Drug Market Share by Country (2021-2026) Table 143. Asia-Pacific Pulmonary Hypertension Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 144. Asia-Pacific Pulmonary Hypertension Drug Market Share Forecast by Country (2027-2032) Table 145. Latin America Pulmonary Hypertension Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 146. Latin America Pulmonary Hypertension Drug Sales by Country (2021-2026) & (W Units) Table 147. Latin America Pulmonary Hypertension Drug Sales Market Share by Country (2021-2026) Table 148. Latin America Pulmonary Hypertension Drug Sales Forecast by Country (2027-2032) & (W Units) Table 149. Latin America Pulmonary Hypertension Drug Sales Market Share Forecast by Country (2027-2032) Table 150. Latin America Pulmonary Hypertension Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 151. Latin America Pulmonary Hypertension Drug Market Size by Country (2021-2026) & (US$ Million) Table 152. Latin America Pulmonary Hypertension Drug Market Share by Country (2021-2026) Table 153. Latin America Pulmonary Hypertension Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 154. Latin America Pulmonary Hypertension Drug Market Share Forecast by Country (2027-2032) Table 155. Middle East and Africa Pulmonary Hypertension Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 156. Middle East and Africa Pulmonary Hypertension Drug Sales by Country (2021-2026) & (W Units) Table 157. Middle East and Africa Pulmonary Hypertension Drug Sales Market Share by Country (2021-2026) Table 158. Middle East and Africa Pulmonary Hypertension Drug Sales Forecast by Country (2027-2032) & (W Units) Table 159. Middle East and Africa Pulmonary Hypertension Drug Sales Market Share Forecast by Country (2027-2032) Table 160. Middle East and Africa Pulmonary Hypertension Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 161. Middle East and Africa Pulmonary Hypertension Drug Market Size by Country (2021-2026) & (US$ Million) Table 162. Middle East and Africa Pulmonary Hypertension Drug Market Share by Country (2021-2026) Table 163. Middle East and Africa Pulmonary Hypertension Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 164. Middle East and Africa Pulmonary Hypertension Drug Market Share Forecast by Country (2027-2032) Table 165. Key Raw Materials Table 166. Raw Materials Key Suppliers Table 167. Pulmonary Hypertension Drug Distributors List Table 168. Pulmonary Hypertension Drug Customers List Table 169. Research Programs/Design for This Report Table 170. Authors List of This Report Table 171. Secondary Sources Table 172. Primary Sources List of Figures Figure 1. Pulmonary Hypertension Drug Image Figure 2. Global Pulmonary Hypertension Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pulmonary Hypertension Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Pulmonary Hypertension Drug Sales (2021-2032) & (W Units) Figure 5. IK-3001 Image Figure 6. Global IK-3001 Sales YoY Growth (2021-2032) & (W Units) Figure 7. Riociguat Image Figure 8. Global Riociguat Sales YoY Growth (2021-2032) & (W Units) Figure 9. Sildenafil Citrate IMD Image Figure 10. Global Sildenafil Citrate IMD Sales YoY Growth (2021-2032) & (W Units) Figure 11. SAR-407899 Image Figure 12. Global SAR-407899 Sales YoY Growth (2021-2032) & (W Units) Figure 13. IK-7002 Image Figure 14. Global IK-7002 Sales YoY Growth (2021-2032) & (W Units) Figure 15. Others Image Figure 16. Global Others Sales YoY Growth (2021-2032) & (W Units) Figure 17. Global Pulmonary Hypertension Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 18. Global Pulmonary Hypertension Drug Market Share by Type 2025 VS 2032 Figure 19. North America Pulmonary Hypertension Drug Sales Market Share in Volume by Type in 2025 Figure 20. North America Pulmonary Hypertension Drug Sales Market Share in Value by Type in 2025 Figure 21. Europe Pulmonary Hypertension Drug Sales Market Share in Volume by Type in 2025 Figure 22. Europe Pulmonary Hypertension Drug Sales Market Share in Value by Type in 2025 Figure 23. Asia-Pacific Pulmonary Hypertension Drug Sales Market Share in Volume by Type in 2025 Figure 24. Asia-Pacific Pulmonary Hypertension Drug Sales Market Share in Value by Type in 2025 Figure 25. Latin America Pulmonary Hypertension Drug Sales Market Share in Volume by Type in 2025 Figure 26. Latin America Pulmonary Hypertension Drug Sales Market Share in Value by Type in 2025 Figure 27. Middle East and Africa Pulmonary Hypertension Drug Sales Market Share in Volume by Type in 2025 Figure 28. Middle East and Africa Pulmonary Hypertension Drug Sales Market Share in Value by Type in 2025 Figure 29. Global Top 5 and 10 Pulmonary Hypertension Drug Players Market Share by Revenue in 2025 Figure 30. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 31. Clinic Image Figure 32. Global Clinic Sales YoY Growth (2021-2032) & (W Units) Figure 33. Hospital Image Figure 34. Global Hospital Sales YoY Growth (2021-2032) & (W Units) Figure 35. Others Image Figure 36. Global Others Sales YoY Growth (2021-2032) & (W Units) Figure 37. Global Pulmonary Hypertension Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 38. Global Pulmonary Hypertension Drug Market Share by Application 2025 VS 2032 Figure 39. North America Pulmonary Hypertension Drug Sales Market Share in Volume by Application in 2025 Figure 40. North America Pulmonary Hypertension Drug Sales Market Share in Value by Application in 2025 Figure 41. Europe Pulmonary Hypertension Drug Sales Market Share in Volume by Application in 2025 Figure 42. Europe Pulmonary Hypertension Drug Sales Market Share in Value by Application in 2025 Figure 43. Asia-Pacific Pulmonary Hypertension Drug Sales Market Share in Volume by Application in 2025 Figure 44. Asia-Pacific Pulmonary Hypertension Drug Sales Market Share in Value by Application in 2025 Figure 45. Latin America Pulmonary Hypertension Drug Sales Market Share in Volume by Application in 2025 Figure 46. Latin America Pulmonary Hypertension Drug Sales Market Share in Value by Application in 2025 Figure 47. Middle East and Africa Pulmonary Hypertension Drug Sales Market Share in Volume by Application in 2025 Figure 48. Middle East and Africa Pulmonary Hypertension Drug Sales Market Share in Value by Application in 2025 Figure 49. North America Pulmonary Hypertension Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 50. North America Pulmonary Hypertension Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. North America Pulmonary Hypertension Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. North America Pulmonary Hypertension Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Pulmonary Hypertension Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 54. Europe Pulmonary Hypertension Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Europe Pulmonary Hypertension Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Europe Pulmonary Hypertension Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Pulmonary Hypertension Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 58. Asia-Pacific Pulmonary Hypertension Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Asia-Pacific Pulmonary Hypertension Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Asia-Pacific Pulmonary Hypertension Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Pulmonary Hypertension Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 62. Latin America Pulmonary Hypertension Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Latin America Pulmonary Hypertension Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Latin America Pulmonary Hypertension Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Pulmonary Hypertension Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 66. Middle East and Africa Pulmonary Hypertension Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 67. Middle East and Africa Pulmonary Hypertension Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 68. Middle East and Africa Pulmonary Hypertension Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 69. Pulmonary Hypertension Drug Value Chain Figure 70. Key Raw Materials Price Figure 71. Manufacturing Cost Structure Figure 72. Pulmonary Hypertension Drug Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • IK-3001
  • Riociguat
  • Sildenafil Citrate IMD
  • SAR-407899
  • IK-7002
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Biolab Sanus Farmaceutica Ltda.
  • Hanmi Pharmaceuticals, Co. Ltd.
  • Ikaria Inc.
  • Proreo Pharma AG
  • Vectura Group plc
  • Vicore Pharma AB
  • Bayer AG
  • Sanofi

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Pulmonary Hypertension Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Pulmonary Hypertension Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Pulmonary Hypertension Drug Market by Type
  6. 1.3.1 IK-3001
  7. 1.3.2 Riociguat
  8. 1.3.3 Sildenafil Citrate IMD
  9. 1.3.4 SAR-407899
  10. 1.3.5 IK-7002
  11. 1.3.6 Others
  12. 1.4 Global Pulmonary Hypertension Drug Market Size by Type
  13. 1.4.1 Global Pulmonary Hypertension Drug Market Size Overview by Type (2021-2032)
  14. 1.4.2 Global Pulmonary Hypertension Drug Historic Market Size Review by Type (2021-2026)
  15. 1.4.3 Global Pulmonary Hypertension Drug Forecasted Market Size by Type (2027-2032)
  16. 1.5 Key Regions Market Size by Type
  17. 1.5.1 North America Pulmonary Hypertension Drug Sales Breakdown by Type (2021-2026)
  18. 1.5.2 Europe Pulmonary Hypertension Drug Sales Breakdown by Type (2021-2026)
  19. 1.5.3 Asia-Pacific Pulmonary Hypertension Drug Sales Breakdown by Type (2021-2026)
  20. 1.5.4 South America Pulmonary Hypertension Drug Sales Breakdown by Type (2021-2026)
  21. 1.5.5 Middle East and Africa Pulmonary Hypertension Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Pulmonary Hypertension Drug Industry Trends
  2. 2.2 Pulmonary Hypertension Drug Industry Drivers
  3. 2.3 Pulmonary Hypertension Drug Industry Opportunities and Challenges
  4. 2.4 Pulmonary Hypertension Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Pulmonary Hypertension Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by Pulmonary Hypertension Drug Sales (2021-2026)
  3. 3.3 Global Top Players by Pulmonary Hypertension Drug Price (2021-2026)
  4. 3.4 Global Pulmonary Hypertension Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Pulmonary Hypertension Drug Major Company Production Sites & Headquarters
  6. 3.6 Global Pulmonary Hypertension Drug Company, Product Type & Application
  7. 3.7 Global Pulmonary Hypertension Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Pulmonary Hypertension Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Pulmonary Hypertension Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Pulmonary Hypertension Drug Tier 1, Tier 2, and Tier 3
4 Pulmonary Hypertension Drug Regional Status and Outlook
  1. 4.1 Global Pulmonary Hypertension Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Pulmonary Hypertension Drug Historic Market Size by Region
  3. 4.2.1 Global Pulmonary Hypertension Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Pulmonary Hypertension Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Pulmonary Hypertension Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Pulmonary Hypertension Drug Forecasted Market Size by Region
  7. 4.3.1 Global Pulmonary Hypertension Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Pulmonary Hypertension Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Pulmonary Hypertension Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Pulmonary Hypertension Drug by Application
  1. 5.1 Pulmonary Hypertension Drug Market by Application
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Pulmonary Hypertension Drug Market Size by Application
  6. 5.2.1 Global Pulmonary Hypertension Drug Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Pulmonary Hypertension Drug Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Pulmonary Hypertension Drug Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Pulmonary Hypertension Drug Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Pulmonary Hypertension Drug Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Pulmonary Hypertension Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Pulmonary Hypertension Drug Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Pulmonary Hypertension Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Biolab Sanus Farmaceutica Ltda.
  2. 6.1.1 Biolab Sanus Farmaceutica Ltda. Company Information
  3. 6.1.2 Biolab Sanus Farmaceutica Ltda. Business Overview
  4. 6.1.3 Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Product Portfolio
  6. 6.1.5 Biolab Sanus Farmaceutica Ltda. Recent Developments
  7. 6.2 Hanmi Pharmaceuticals, Co. Ltd.
  8. 6.2.1 Hanmi Pharmaceuticals, Co. Ltd. Company Information
  9. 6.2.2 Hanmi Pharmaceuticals, Co. Ltd. Business Overview
  10. 6.2.3 Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Product Portfolio
  12. 6.2.5 Hanmi Pharmaceuticals, Co. Ltd. Recent Developments
  13. 6.3 Ikaria Inc.
  14. 6.3.1 Ikaria Inc. Company Information
  15. 6.3.2 Ikaria Inc. Business Overview
  16. 6.3.3 Ikaria Inc. Pulmonary Hypertension Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Ikaria Inc. Pulmonary Hypertension Drug Product Portfolio
  18. 6.3.5 Ikaria Inc. Recent Developments
  19. 6.4 Proreo Pharma AG
  20. 6.4.1 Proreo Pharma AG Company Information
  21. 6.4.2 Proreo Pharma AG Business Overview
  22. 6.4.3 Proreo Pharma AG Pulmonary Hypertension Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Proreo Pharma AG Pulmonary Hypertension Drug Product Portfolio
  24. 6.4.5 Proreo Pharma AG Recent Developments
  25. 6.5 Vectura Group plc
  26. 6.5.1 Vectura Group plc Company Information
  27. 6.5.2 Vectura Group plc Business Overview
  28. 6.5.3 Vectura Group plc Pulmonary Hypertension Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Vectura Group plc Pulmonary Hypertension Drug Product Portfolio
  30. 6.5.5 Vectura Group plc Recent Developments
  31. 6.6 Vicore Pharma AB
  32. 6.6.1 Vicore Pharma AB Company Information
  33. 6.6.2 Vicore Pharma AB Business Overview
  34. 6.6.3 Vicore Pharma AB Pulmonary Hypertension Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Vicore Pharma AB Pulmonary Hypertension Drug Product Portfolio
  36. 6.6.5 Vicore Pharma AB Recent Developments
  37. 6.7 Bayer AG
  38. 6.7.1 Bayer AG Company Information
  39. 6.7.2 Bayer AG Business Overview
  40. 6.7.3 Bayer AG Pulmonary Hypertension Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Bayer AG Pulmonary Hypertension Drug Product Portfolio
  42. 6.7.5 Bayer AG Recent Developments
  43. 6.8 Sanofi
  44. 6.8.1 Sanofi Company Information
  45. 6.8.2 Sanofi Business Overview
  46. 6.8.3 Sanofi Pulmonary Hypertension Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Sanofi Pulmonary Hypertension Drug Product Portfolio
  48. 6.8.5 Sanofi Recent Developments
7 North America by Country
  1. 7.1 North America Pulmonary Hypertension Drug Sales by Country
  2. 7.1.1 North America Pulmonary Hypertension Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Pulmonary Hypertension Drug Sales by Country (2021-2026)
  4. 7.1.3 North America Pulmonary Hypertension Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America Pulmonary Hypertension Drug Market Size by Country
  6. 7.2.1 North America Pulmonary Hypertension Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Pulmonary Hypertension Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America Pulmonary Hypertension Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Pulmonary Hypertension Drug Sales by Country
  2. 8.1.1 Europe Pulmonary Hypertension Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Pulmonary Hypertension Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe Pulmonary Hypertension Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Pulmonary Hypertension Drug Market Size by Country
  6. 8.2.1 Europe Pulmonary Hypertension Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Pulmonary Hypertension Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe Pulmonary Hypertension Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Pulmonary Hypertension Drug Sales by Country
  2. 9.1.1 Asia-Pacific Pulmonary Hypertension Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Pulmonary Hypertension Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Pulmonary Hypertension Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Pulmonary Hypertension Drug Market Size by Country
  6. 9.2.1 Asia-Pacific Pulmonary Hypertension Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Pulmonary Hypertension Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Pulmonary Hypertension Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Pulmonary Hypertension Drug Sales by Country
  2. 10.1.1 South America Pulmonary Hypertension Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Pulmonary Hypertension Drug Sales by Country (2021-2026)
  4. 10.1.3 South America Pulmonary Hypertension Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America Pulmonary Hypertension Drug Market Size by Country
  6. 10.2.1 South America Pulmonary Hypertension Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Pulmonary Hypertension Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America Pulmonary Hypertension Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Pulmonary Hypertension Drug Sales by Country
  2. 11.1.1 Middle East and Africa Pulmonary Hypertension Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Pulmonary Hypertension Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Pulmonary Hypertension Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Pulmonary Hypertension Drug Market Size by Country
  6. 11.2.1 Middle East and Africa Pulmonary Hypertension Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Pulmonary Hypertension Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Pulmonary Hypertension Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Pulmonary Hypertension Drug Value Chain Analysis
  2. 12.1.1 Pulmonary Hypertension Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Pulmonary Hypertension Drug Production Mode & Process
  7. 12.2 Pulmonary Hypertension Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Pulmonary Hypertension Drug Distributors
  10. 12.2.3 Pulmonary Hypertension Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst